Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He ...
The Jehovah’s Witnesses have partly eased their long-standing prohibition on the medical use of donated blood, allowing ...
The U.S. is working on rules for investing in China that would likely preserve pharma's ability to strike most licensing ...
We’re very actively hiring,” Karim Mikhail, director of FDA’s Center for Biologics Evaluation and Research, told drug ...
Kennedy Jr. named eight new members to the U.S. Preventive Services Task Force, an influential panel of experts who assess ...
Over the past 25 years, there’s been a dramatic change in how we understand children who don’t “listen,” writes behavioral ...
As part of broad drug pricing deals with the Trump administration, more than two dozen pharma companies agreed to sell drugs to state Medicaid programs at prices available in peer countries under ...
The FDA approved a new gene therapy for Sanfilippo syndrome type A, an ultra-rare disease sometimes known as childhood ...
The lawsuit seeks to halt the process of searching grant applications for specific terms to determine if they should be ...
A breast cancer drug from AstraZeneca will now be available in England after a pricing deal was reached, in part a result of ...
Cautious optimism in the Ebola outbreak, FDA still stymied by DOGE cuts, and other health updates from the Morning Rounds ...
The young men in my clinic are responding rationally to a system that was designed for profit,” writes plastic surgeon Kavitha Ranganathan.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results